Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis

Rheumatology

Volumn 42, Issue 11, 2003, Pages 1383-1389

  Foell, D ^a   Kane, D ^b   Bresnihan, B ^b   Vogl, T ^a   Nacken, W ^a   Sorg, C ^a   FitzGerald, O ^b   Roth, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Calgranulin C; Neutrophils; Psoriatic arthritis; RAGE; S100A12; Synovitis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALGRANULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIUM; FEMALE; GRANULOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RECEPTOR BINDING; REMISSION; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUTROPHILS; S100 PROTEINS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

EID: 0242441020     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg385     Document Type: Article

References (40)

1. Bresnihan B, Tak PP. Synovial tissue analysis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:645-59.
2. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
3. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-56.
4. Biasi D, Carletto A, Caramaschi P et al. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflammation 1998;22:533-43.
5. Mikulikova D, Stancikova M, Trnavsky K, Vlcek F. Activity of some lysosomal enzyme in rheumatoid and psoriatic arthritis. Clin Rheumatol 1984;3:515-9.
6. Sedgwick JB, Bergstresser PR, Hurd ER. Increased granulocyte adherence in psoriasis and psoriatic arthritis. J Invest Dermatol 1980;74:81-4.
7. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4.
8. Fearon U, Reece R, Smith J, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci 1999;878:619-21.
9. Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;44:2024-8.
10. Lowe PM, Lee ML, Jackson CJ, To SS, Cooper AJ, Schrieber L. The endothelium in psoriasis. Br J Dermatol 1995;132:497-505.
11. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
12. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-502.
13. Clohessy PA, Golden BE. Elevated plasma levels of L1L and L1H in CF patients. Biochem Soc Trans 1996;24:310S.
14. Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996;74:136-9.
15. Frosch M, Strey A, Vogl T et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43:628-37.
16. Roth J, Goebeler M, Sorg C. S100A8 and S100A9 in inflammatory diseases. Lancet 2001;357:1041.
17. Vogl T, Propper C, Hartmann M et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999; 274:25291-6.
18. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901.
19. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001;69:986-94.
20. Robinson MJ, Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun 2000;275:865-70.
21. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000;21:665-72.
22. Miranda LP, Tao T, Jones A et al. Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett 2001;488:85-90.
23. Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001;50:1495-504.
24. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;1272:17810-4.
25. Ritchie DM, Boyle JA, McInnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
26. van den Bos C, Rammes A, Vogl T et al. Copurification of P6, MRP8, and MRP14 from human granulocytes and separation of individual proteins. Protein Expr Purif 1998;13:313-8.
27. Brook M, Sully G, Clark AR, Saklatvala J. Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett 2000;483:57-61.
28. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
29. Feldmann M, Maini RN, Bondeson J, Taylor P, Foxwell BM, Brennan FM. Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol 2001;490:119-27.
30. Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
31. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
32. Youssef P, Roth J, Frosch M et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999;26:2523-8.
33. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4: 1025-31.
34. Wendt T, Bucciarelli L, Qu W et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002; 4:228-37.
35. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1-15.
36. Yamamoto Y, Yamagishi S, Yonekura H et al. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci 2000;902:163-70; discussion 170-2.
37. Twigg SM, Chen MM, Joly AH et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001;142:1760-9.
38. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105:816-22.
39. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998;37:502-8.
40. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000;43:1488-95.